Recent advances in immunotherapies: from infection and autoimmunity, to cancer, and back again (Q58087985)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30376867 AND SRC:MED&resulttype=core&format=json

1 May 2020

2 references

8 February 2021

24 June 2021

Recent advances in immunotherapies: from infection and autoimmunity, to cancer, and back again (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30376867 AND SRC:MED&resulttype=core&format=json

1 May 2020

2 references

9 September 2020

1 reference

8 February 2021

1 reference

24 June 2021

2

Jeffrey A Bluestone

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30376867 AND SRC:MED&resulttype=core&format=json

1 May 2020

author name string

Samantha L Bucktrout

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30376867 AND SRC:MED&resulttype=core&format=json

1 May 2020

Fred Ramsdell

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30376867 AND SRC:MED&resulttype=core&format=json

1 May 2020

language of work or name

English

0 references

publication date

31 October 2018

4 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30376867 AND SRC:MED&resulttype=core&format=json

1 May 2020

9 September 2020

8 February 2021

24 June 2021

4 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30376867 AND SRC:MED&resulttype=core&format=json

1 May 2020

9 September 2020

8 February 2021

24 June 2021

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30376867 AND SRC:MED&resulttype=core&format=json

1 May 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30376867 AND SRC:MED&resulttype=core&format=json

1 May 2020

page(s)

79

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30376867 AND SRC:MED&resulttype=core&format=json

Creative Commons Attribution 4.0 International

1 May 2020

copyright license

2 references

8 February 2021

Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4lg

24 June 2021

cites work

1 reference

12 December 2020

Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death

1 reference

12 December 2020

Coley's toxins in perspective

1 reference

12 December 2020

Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4

1 reference

12 December 2020

Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4

1 reference

12 December 2020

CTLA-4 can function as a negative regulator of T cell activation

1 reference

12 December 2020

Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response

1 reference

12 December 2020

Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor

1 reference

12 December 2020

Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma

1 reference

12 December 2020

Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation

1 reference

12 December 2020

Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice

1 reference

12 December 2020

PD-L2 is a second ligand for PD-1 and inhibits T cell activation

1 reference

12 December 2020

Identification of a protein fragment of interleukin 2 responsible for vasopermeability

1 reference

12 December 2020

PD-1 inhibits antiviral immunity at the effector phase in the liver

1 reference

12 December 2020

SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation

1 reference

12 December 2020

Edward Jenner and the history of smallpox and vaccination

1 reference

12 December 2020

CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms

1 reference

12 December 2020

Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial.

1 reference

12 December 2020

Insulin-induced remission in new-onset NOD mice is maintained by the PD-1-PD-L1 pathway.

1 reference

12 December 2020

Programmed death ligand 1 regulates a critical checkpoint for autoimmune myocarditis and pneumonitis in MRL mice

1 reference

12 December 2020

CTLA-4 control over Foxp3 regulatory T cell function

1 reference

12 December 2020

Phase I/II study of ipilimumab for patients with metastatic melanoma

1 reference

12 December 2020

The initial phase of an immune response functions to activate regulatory T cells

1 reference

12 December 2020

Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal.

1 reference

12 December 2020

Mechanisms underlying lineage commitment and plasticity of helper CD4 T cells

1 reference

12 December 2020

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

1 reference

12 December 2020

Emerging principles in protease-based drug discovery

1 reference

12 December 2020

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

1 reference

12 December 2020

Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4

1 reference

12 December 2020

Decisions about dendritic cells: past, present, and future

1 reference

12 December 2020

The immune contexture in human tumours: impact on clinical outcome

1 reference

12 December 2020

Management of immune-related adverse events and kinetics of response with ipilimumab

1 reference

12 December 2020

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

1 reference

12 December 2020

Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma

1 reference

12 December 2020

A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C.

1 reference

12 December 2020

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

1 reference

12 December 2020

Nivolumab plus ipilimumab in advanced melanoma

1 reference

12 December 2020

Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma

1 reference

12 December 2020

Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma

1 reference

12 December 2020

PD-1 identifies the patient-specific CD8⁺ tumor-reactive repertoire infiltrating human tumors

1 reference

12 December 2020

Protein kinase C-η controls CTLA-4-mediated regulatory T cell function

1 reference

12 December 2020

STAT3, STAT4, NFATc1, and CTCF regulate PD-1 through multiple novel regulatory regions in murine T cells

1 reference

12 December 2020

Improved survival with T cell clonotype stability after anti-CTLA-4 treatment in cancer patients

1 reference

12 December 2020

Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4

1 reference

12 December 2020

Anti-CTLA-4 therapy broadens the melanoma-reactive CD8 T cell response.

1 reference

12 December 2020

T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial

1 reference

12 December 2020

PD-1 blockade induces responses by inhibiting adaptive immune resistance

1 reference

12 December 2020

Safety, correlative markers, and clinical results of adjuvant nivolumab in combination with vaccine in resected high-risk metastatic melanoma

1 reference

12 December 2020

Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma

1 reference

12 December 2020

Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

1 reference

12 December 2020

The future of immune checkpoint therapy

1 reference

12 December 2020

The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases

1 reference

12 December 2020

Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients

1 reference

12 December 2020

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

1 reference

12 December 2020

T-cell exhaustion, co-stimulation and clinical outcome in autoimmunity and infection.

1 reference

12 December 2020

Molecular and cellular insights into T cell exhaustion

1 reference

12 December 2020

Combination cancer immunotherapy and new immunomodulatory targets

1 reference

12 December 2020

T cell metabolism drives immunity

1 reference

12 December 2020

Genomic correlates of response to CTLA-4 blockade in metastatic melanoma

1 reference

12 December 2020

Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes.

1 reference

12 December 2020

Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders.

1 reference

12 December 2020

Patterns of Clinical Response with Talimogene Laherparepvec (T-VEC) in Patients with Melanoma Treated in the OPTiM Phase III Clinical Trial

1 reference

12 December 2020

Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease

1 reference

12 December 2020

Tumor immune profiling predicts response to anti-PD-1 therapy in human melanoma.

1 reference

12 December 2020

Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial

1 reference

12 December 2020

Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab.

1 reference

12 December 2020

Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer

1 reference

12 December 2020

Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade

1 reference

12 December 2020

The epigenetic landscape of T cell exhaustion.

1 reference

12 December 2020

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.

1 reference

12 December 2020

Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma

1 reference

12 December 2020

Elements of cancer immunity and the cancer-immune set point

1 reference

12 December 2020

Targeting neoantigens to augment antitumour immunity

1 reference

12 December 2020

T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition.

1 reference

12 December 2020

Obstacles Posed by the Tumor Microenvironment to T cell Activity: A Case for Synergistic Therapies.

1 reference

12 December 2020

T-cell invigoration to tumour burden ratio associated with anti-PD-1 response.

1 reference

12 December 2020

Is autoimmunity the Achilles' heel of cancer immunotherapy?

1 reference

12 December 2020

Chromatin states define tumour-specific T cell dysfunction and reprogramming.

1 reference

12 December 2020

Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade

1 reference

12 December 2020

Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy.

1 reference

12 December 2020

First FDA Approval Agnostic of Cancer Site - When a Biomarker Defines the Indication

1 reference

12 December 2020

Avidity and Bystander Suppressive Capacity of Human Regulatory T Cells Expressing De Novo Autoreactive T-Cell Receptors in Type 1 Diabetes

1 reference

12 December 2020

Implications of the tumor immune microenvironment for staging and therapeutics

1 reference

12 December 2020

Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy

1 reference

12 December 2020

Tumor Mutational Burden and Response Rate to PD-1 Inhibition.

1 reference

12 December 2020

Cancer Immunotherapy Targets Based on Understanding the T Cell-Inflamed Versus Non-T Cell-Inflamed Tumor Microenvironment.

1 reference

12 December 2020

Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia

1 reference

12 December 2020

TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells.

1 reference

12 December 2020

Selective targeting of engineered T cells using orthogonal IL-2 cytokine-receptor complexes.

1 reference

12 December 2020

Genetic mechanisms of immune evasion in colorectal cancer

1 reference

12 December 2020

Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis.

1 reference

12 December 2020

CAR T cell immunotherapy for human cancer.

1 reference

12 December 2020

The Immune Landscape of Cancer.

1 reference

12 December 2020

Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer.

1 reference

12 December 2020

T-cell Responses to TP53 "Hotspot" Mutations and Unique Neoantigens Expressed by Human Ovarian Cancers

1 reference

12 December 2020

A transcriptionally and functionally distinct PD-1 CD8 T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade

1 reference

12 December 2020

Combining vaccines and immune checkpoint inhibitors to prime, expand, and facilitate effective tumor immunotherapy

1 reference

12 December 2020

TIGIT and PD-1 dual checkpoint blockade enhances antitumor immunity and survival in GBM.

1 reference

12 December 2020

Expression of LAG-3 and efficacy of combination treatment with anti-LAG-3 and anti-PD-1 monoclonal antibodies in glioblastoma

1 reference

12 December 2020

10.1186/S13073-018-0588-4

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30376867 AND SRC:MED&resulttype=core&format=json

1 May 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30376867 AND SRC:MED&resulttype=core&format=json

1 May 2020

PubMed publication ID

30376867

1 reference